CoChat

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Open access

Published version of a preprint

The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.

Abstract

The desmoplastic stroma in solid tumors presents a formidable challenge to immunotherapies that rely on endogenous or adoptively transferred T cells, however, the mechanisms are poorly understood. To define mechanisms involved, here we treat established desmoplastic pancreatic tumors with CAR T cells directed to fibroblast activation protein (FAP), an enzyme highly overexpressed on a subset of cancer-associated fibroblasts (CAFs). Depletion of FAP + CAFs results in loss of the structural integrity of desmoplastic matrix. This renders these highly treatment-resistant cancers susceptible to subsequent treatment with a tumor antigen (mesothelin)-targeted CAR T cells and to anti-PD-1 antibody therapy. Mechanisms include overcoming stroma-dependent restriction of T cell extravasation and/or perivascular invasion, reversing immune exclusion, relieving T cell suppression, and altering the immune landscape by reducing myeloid cell accumulation and increasing endogenous CD8 + T cell and NK cell infiltration. These data provide strong rationale for combining tumor stroma- and malignant cell-targeted therapies to be tested in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-40850-5

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Stromal-targeted FAP-CAR T cells inhibit PDAC tumor growth more effectively than Meso-CAR T cells. a Depiction of control MigR, Meso-CAR and FAP-CAR recombinant MigR constructs. b–d Comparable transduction efficiency, CAR expression and function of FAP- and Meso-CAR T cells in vitro. b Flow cytometric analysis of EGFP expression (Y-axis) and reactivity with CAR binding APC-conjugated anti-F(ab’)2 fragment antibodies (X-axis). c Cytotoxic activity and d IFN-γ release when T cells were cultured with target cells expressing their specific targets, Meso+ 4662 tumor cells and murine FAP transfected 3T3 cells, relative to negative control Meso-KO 4662 cells and FAP-negative parental 3T3 cells, respectively (n = 3 independent samples/group). Data points are mean±SD and groups were compared using two-way ANOVA with Tukey’s multiple comparisons test. ****p < 0.0001. e–l Impact of FAP-CAR T vs. Meso-CAR T on growth of established 4662 tumors subcutaneously transplanted into syngeneic mice and (j–l) established spontaneous pancreatic tumors in KPC mice. e Experimental timeline for treatment of 4662 syngeneic PDAC tumor bearing C57BL/6 mice. Average (f) and individual (g) growth curves, tumor weight at endpoint (h) and modified Kaplan-Meier curves (i) for each treatment cohort in the syngeneic transplant model. j Schematic of KPC autochthonous tumor model experimental design. Average tumor growth curves measured by ultrasound (k) and modified Kaplan-Meier plots (l) for KPC mice with indicated treatments. Data indicate mean±SD (n = 5 per group) and were determined by one-way ANOVA with Tukey’s multiple comparisons test (f, h, and k) or log-rank test (i and l). j The pancreas and ultrasound are created with BioRender.com. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. h PBS vs. Meso-CAR, p = 0.032; PBS vs. FAP-CAR, p = 0.002; MigR vs. FAP-CAR, p = 0.010. i. PBS vs. Meso-CAR, p = 0.049; MigR vs. FAP-CAR, p = 0.004; Meso-CAR vs. FAP-CAR, p = 0.020. k. MigR vs. Meso-CAR, p = 0.029. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 1 Stromal-targeted FAP-CAR T cells inhibit PDAC tumor growth more effectively than Meso-CAR T cells. a Depiction of control MigR, Meso-CAR and FAP-CAR recombinant MigR constructs. b–d Comparable transduction efficiency, CAR expression and function of FAP- and Meso-CAR T cells in vitro. b Flow cytometric analysis of EGFP expression (Y-axis) and reactivity with CAR binding APC-conjugated anti-F(ab’)2 fragment antibodies (X-axis). c Cytotoxic activity and d IFN-γ release when T cells were cultured with target cells expressing their specific targets, Meso+ 4662 tumor cells and murine FAP transfected 3T3 cells, relative to negative control Meso-KO 4662 cells and FAP-negative parental 3T3 cells, respectively (n = 3 independent samples/group). Data points are mean±SD and groups were compared using two-way ANOVA with Tukey’s multiple comparisons test. ****p < 0.0001. e–l Impact of FAP-CAR T vs. Meso-CAR T on growth of established 4662 tumors subcutaneously transplanted into syngeneic mice and (j–l) established spontaneous pancreatic tumors in KPC mice. e Experimental timeline for treatment of 4662 syngeneic PDAC tumor bearing C57BL/6 mice. Average (f) and individual (g) growth curves, tumor weight at endpoint (h) and modified Kaplan-Meier curves (i) for each treatment cohort in the syngeneic transplant model. j Schematic of KPC autochthonous tumor model experimental design. Average tumor growth curves measured by ultrasound (k) and modified Kaplan-Meier plots (l) for KPC mice with indicated treatments. Data indicate mean±SD (n = 5 per group) and were determined by one-way ANOVA with Tukey’s multiple comparisons test (f, h, and k) or log-rank test (i and l). j The pancreas and ultrasound are created with BioRender.com. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. h PBS vs. Meso-CAR, p = 0.032; PBS vs. FAP-CAR, p = 0.002; MigR vs. FAP-CAR, p = 0.010. i. PBS vs. Meso-CAR, p = 0.049; MigR vs. FAP-CAR, p = 0.004; Meso-CAR vs. FAP-CAR, p = 0.020. k. MigR vs. Meso-CAR, p = 0.029. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 FAP-CAR T cells infiltrate and deplete their target cells more effectively than Meso-CAR T cells in PDAC tumors. a Schematic of experimental protocol. b Left: representative flow cytometry plots of tumor-infiltrating MigR control, Meso-CAR, and FAP-CAR T cells. Right: The number of CD45.1+GFP+ CAR T cells recovered per 0.2 grams of tumor tissue (top) and the percent of CD45.1+GFP+ CAR T cells amongst total live cells recovered (bottom) at each time point for each group. Representative flow cytometry analysis and quantification of PD-1 (c), Ki-67 (d) and IFN-γ (e) expression in the tumor-infiltrating MigR control, Meso-CAR and FAP-CAR T cells at day 7 post-administration. f Quantification of flow cytometric analysis on FAP+ cells (top), Pearson correlation analysis on FAP+ cells with the extent of tumor-infiltrating FAP-CAR T cells (middle), and quantification of flow cytometric analysis on mesothelin+ cells (bottom). g Representative multiplex IF images (left) showing the localization of CAR T cells and their spatial relationships to FAP+ stromal cells and EpCAM+ tumor cells in syngenetic transplanted 4622 tumors. Quantification is depicted in the adjacent bar graphs (right). h Representative multiplex IF images (left) showing the localization of CAR T cells and their spatial relationships to FAP+ stromal cells and PanCK+ tumor cells in spontaneous pancreatic tumors in KPC mice. Quantification is depicted in the adjacent bar graphs (right). Data points are mean±SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (c–e, h) or two-way ANOVA with Tukey’s multiple comparisons tests (b, f, g). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. b top panel Day 1: MigR vs. FAP-CAR, p = 0.040; Meso-CAR vs. FAP-CAR, p = 0.026. bottom panel Day 1: MigR vs. FAP-CAR, p = 0.011; Meso-CAR vs. FAP-CAR, p = 0.012. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 2 FAP-CAR T cells infiltrate and deplete their target cells more effectively than Meso-CAR T cells in PDAC tumors. a Schematic of experimental protocol. b Left: representative flow cytometry plots of tumor-infiltrating MigR control, Meso-CAR, and FAP-CAR T cells. Right: The number of CD45.1+GFP+ CAR T cells recovered per 0.2 grams of tumor tissue (top) and the percent of CD45.1+GFP+ CAR T cells amongst total live cells recovered (bottom) at each time point for each group. Representative flow cytometry analysis and quantification of PD-1 (c), Ki-67 (d) and IFN-γ (e) expression in the tumor-infiltrating MigR control, Meso-CAR and FAP-CAR T cells at day 7 post-administration. f Quantification of flow cytometric analysis on FAP+ cells (top), Pearson correlation analysis on FAP+ cells with the extent of tumor-infiltrating FAP-CAR T cells (middle), and quantification of flow cytometric analysis on mesothelin+ cells (bottom). g Representative multiplex IF images (left) showing the localization of CAR T cells and their spatial relationships to FAP+ stromal cells and EpCAM+ tumor cells in syngenetic transplanted 4622 tumors. Quantification is depicted in the adjacent bar graphs (right). h Representative multiplex IF images (left) showing the localization of CAR T cells and their spatial relationships to FAP+ stromal cells and PanCK+ tumor cells in spontaneous pancreatic tumors in KPC mice. Quantification is depicted in the adjacent bar graphs (right). Data points are mean±SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (c–e, h) or two-way ANOVA with Tukey’s multiple comparisons tests (b, f, g). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. b top panel Day 1: MigR vs. FAP-CAR, p = 0.040; Meso-CAR vs. FAP-CAR, p = 0.026. bottom panel Day 1: MigR vs. FAP-CAR, p = 0.011; Meso-CAR vs. FAP-CAR, p = 0.012. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 FAP-CAR T cells overcome the physical barrier and immunosuppressive TME to infiltrate tumor nests. a Workflow for two-photon microscopy. b Representative two-photon images at subregions of tumors treated with MigR, Meso-CAR, or FAP-CAR T cells at indicated timepoints. GFP+ T cells (green, red arrows), stromal cells (magenta), tumor cells (cyan), and SHG (gray). Scale bar, 100 µm. c Quantification of GFP+ T cells, stromal cells, SHG fiber number, and SHG+ area in stroma-rich (left) and tumor nests (right) at indicated timepoints. d Quantification of T cell motility (left; mean track speed; middle, track length; right, track straightness) for MigR, Meso-CAR, and FAP-CAR T cells at day 7 post-administration. e Quantification of FAP-CAR T cell mobility in stroma-rich (top) and tumor nest (bottom) regions at indicated timepoints. a Created with BioRender.com. Data points (15 per condition) in c represent measurements in 3 different fields of stroma-rich and 3 different fields of tumor-nest regions from tumor slices from 5 mice per group. Data points in d, e represent the quantification of motility of all individual T cells (identified unbiasedly by Imaris) in the 3 most stroma-rich regions and the 3 most tumor cell-rich (nest) regions amongst 6 systematically selected fields for one slice from each of 5 tumors per group; bars, mean ± SD. Groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests (c) or one-way ANOVA analysis with Dunnett’s multiple comparison tests d, e. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c T cells (left): Day 1 MigR/Meso-CAR vs. FAP-CAR, p = 0.003 and 0.004, respectively. Fiber number: left Day 4 MigR/Meso-CAR vs. FAP-CAR, p = 0.004 and 0.013, respectively; right Day 7 MigR/Meso-CAR vs. FAP-CAR, p = 0.001 and 0.007, respectively. SHG area (right): Day 7 MigR vs. FAP-CAR, p = 0.004. d. track speed: MigR/Meso-CAR vs. FAP-CAR, p = 0.002 and 0.012, respectively. e track straightness (left): Day 4 vs. 7, p = 0.009. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 3 FAP-CAR T cells overcome the physical barrier and immunosuppressive TME to infiltrate tumor nests. a Workflow for two-photon microscopy. b Representative two-photon images at subregions of tumors treated with MigR, Meso-CAR, or FAP-CAR T cells at indicated timepoints. GFP+ T cells (green, red arrows), stromal cells (magenta), tumor cells (cyan), and SHG (gray). Scale bar, 100 µm. c Quantification of GFP+ T cells, stromal cells, SHG fiber number, and SHG+ area in stroma-rich (left) and tumor nests (right) at indicated timepoints. d Quantification of T cell motility (left; mean track speed; middle, track length; right, track straightness) for MigR, Meso-CAR, and FAP-CAR T cells at day 7 post-administration. e Quantification of FAP-CAR T cell mobility in stroma-rich (top) and tumor nest (bottom) regions at indicated timepoints. a Created with BioRender.com. Data points (15 per condition) in c represent measurements in 3 different fields of stroma-rich and 3 different fields of tumor-nest regions from tumor slices from 5 mice per group. Data points in d, e represent the quantification of motility of all individual T cells (identified unbiasedly by Imaris) in the 3 most stroma-rich regions and the 3 most tumor cell-rich (nest) regions amongst 6 systematically selected fields for one slice from each of 5 tumors per group; bars, mean ± SD. Groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests (c) or one-way ANOVA analysis with Dunnett’s multiple comparison tests d, e. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c T cells (left): Day 1 MigR/Meso-CAR vs. FAP-CAR, p = 0.003 and 0.004, respectively. Fiber number: left Day 4 MigR/Meso-CAR vs. FAP-CAR, p = 0.004 and 0.013, respectively; right Day 7 MigR/Meso-CAR vs. FAP-CAR, p = 0.001 and 0.007, respectively. SHG area (right): Day 7 MigR vs. FAP-CAR, p = 0.004. d. track speed: MigR/Meso-CAR vs. FAP-CAR, p = 0.002 and 0.012, respectively. e track straightness (left): Day 4 vs. 7, p = 0.009. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Ablation of FAP+ cells alters the stromal landscape, rapidly depletes matrix and enhances T cell infiltration. a Representative (top) and quantification of (bottom) multiplex immunofluorescence images in tumors 1 week (left) and 2 weeks (right) post-treatment with PBS, MigR control or FAP-CAR T cells. First row depicts staining for stromal cell profiles, including FAP (green), α-SMA (red) and PDGFR-α (magenta). Second row depicts staining for ECM components including collagen hybridizing peptide (CHP) that detects remodeled collagen (red) and FN (green). Third row depicts distribution of T cells (CD3, red) and their spatial relationships to tumor cells (PanCK, green) and stromal cells (PDPN, magenta). Nuclei were stained with DAPI (blue). Scale bar: 100 μm. b t-SNE of multi-parametric flow cytometry demonstrating the immune cell profiles based on the gating strategy as depicted in Supplementary Fig. 8, including lymphocyte (left) and myeloid cells (right) in tumors 1 week (Top row) and 2 weeks (bottom row) post-treatment with PBS, MigR control or FAP-CAR T cells. The percentages of indicated immune cell subpopulations in total live cells or CD45.2+ cells from tumors for each group of mice quantified based on multi-parametric flow cytometry analysis. Data points are mean ± SD (n = 5 per group) and groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. a. PDGFRα (post 1 week): PBS vs. FAP-CAR, p = 0.032. PDGFRα (post 2 weeks): PBS vs. FAP-CAR, p = 0.002. Fibronectin (post 1 week): MigR vs. FAP-CAR, p = 0.022. CD3 (post 1 week): MigR vs. FAP-CAR, p = 0.005. PanCK (post 2 weeks): MigR vs. FAP-CAR, p = 0.004. b post 1 week: CD3 PBS vs. FAP-CAR, p = 0.047. CD8 PBS vs. FAP-CAR, p = 0.004, MigR vs. FAP-CAR, p = 0.020. post 2 weeks: Ly6ClowLy6G+ MigR vs. FAP-CAR, p = 0.006. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 4 Ablation of FAP+ cells alters the stromal landscape, rapidly depletes matrix and enhances T cell infiltration. a Representative (top) and quantification of (bottom) multiplex immunofluorescence images in tumors 1 week (left) and 2 weeks (right) post-treatment with PBS, MigR control or FAP-CAR T cells. First row depicts staining for stromal cell profiles, including FAP (green), α-SMA (red) and PDGFR-α (magenta). Second row depicts staining for ECM components including collagen hybridizing peptide (CHP) that detects remodeled collagen (red) and FN (green). Third row depicts distribution of T cells (CD3, red) and their spatial relationships to tumor cells (PanCK, green) and stromal cells (PDPN, magenta). Nuclei were stained with DAPI (blue). Scale bar: 100 μm. b t-SNE of multi-parametric flow cytometry demonstrating the immune cell profiles based on the gating strategy as depicted in Supplementary Fig. 8, including lymphocyte (left) and myeloid cells (right) in tumors 1 week (Top row) and 2 weeks (bottom row) post-treatment with PBS, MigR control or FAP-CAR T cells. The percentages of indicated immune cell subpopulations in total live cells or CD45.2+ cells from tumors for each group of mice quantified based on multi-parametric flow cytometry analysis. Data points are mean ± SD (n = 5 per group) and groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. a. PDGFRα (post 1 week): PBS vs. FAP-CAR, p = 0.032. PDGFRα (post 2 weeks): PBS vs. FAP-CAR, p = 0.002. Fibronectin (post 1 week): MigR vs. FAP-CAR, p = 0.022. CD3 (post 1 week): MigR vs. FAP-CAR, p = 0.005. PanCK (post 2 weeks): MigR vs. FAP-CAR, p = 0.004. b post 1 week: CD3 PBS vs. FAP-CAR, p = 0.047. CD8 PBS vs. FAP-CAR, p = 0.004, MigR vs. FAP-CAR, p = 0.020. post 2 weeks: Ly6ClowLy6G+ MigR vs. FAP-CAR, p = 0.006. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Ablation of FAP+ cells by FAP-CAR T cells enhances the efficacy of anti-PD-1 antibody immune checkpoint therapy. a Treatment protocol: 4662 tumor-bearing CD45.2 C57BL/6 mice were treated with MigR control or FAP-CAR T cells followed by isotype or anti-PD-1 antibodies. b Average tumor growth curves, c individual tumor growth curves, d end-point tumor weights, and e modified Kaplan-Meier curve for mice in each of the indicated treatment groups. f Quantification of tumor-infiltrating MigR control or FAP-CAR T cells expressing both CD45.1 and EGFP, FAP+ cells and PD-1 expression in endogenous CD8+ T cells in tumors at end-point. g Representative multiplex IF images and h quantification of FAP (green) and α-SMA (red) (top row), as well as CD8 (green) and PD-1 (red) (bottom row) in end-point tumors for indicated treatment groups. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. i Quantification of tumor infiltrating endogenous CD8+ T cells and total Tim-3+, TNF-α+, and IFN-γ+ T cells upon re-stimulation ex vivo based on flow cytometry analysis. Data points are mean ± SD (n = 8 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b, d, f, h, and i) or log-rank test (e). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. e MigR+IgG/MigR+anti-PD-1/ FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.004, 0.003 and 0.028, respectively. f CAR T cells: FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.015. g PD-1+ cells: MigR+IgG vs. MigR+Anti-PD-1, p = 0.030; MigR+IgG vs. FAP-CAR+IgG, p = 0.003. i upper left panel: MigR+IgG vs. FAP-CAR+IgG, p = 0.008; FAP+IgG vs. FAP-CAR+anti-PD-1, p = 0.004. upper right panel: MigR+IgG vs. FAP-CAR+IgG, p = 0.003; MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.032; FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.025. Bottom panel: TNF-α MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.012; IFN-γ MigR+IgG vs. FAP-CAR+IgG, p = 0.009; MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.015. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 5 Ablation of FAP+ cells by FAP-CAR T cells enhances the efficacy of anti-PD-1 antibody immune checkpoint therapy. a Treatment protocol: 4662 tumor-bearing CD45.2 C57BL/6 mice were treated with MigR control or FAP-CAR T cells followed by isotype or anti-PD-1 antibodies. b Average tumor growth curves, c individual tumor growth curves, d end-point tumor weights, and e modified Kaplan-Meier curve for mice in each of the indicated treatment groups. f Quantification of tumor-infiltrating MigR control or FAP-CAR T cells expressing both CD45.1 and EGFP, FAP+ cells and PD-1 expression in endogenous CD8+ T cells in tumors at end-point. g Representative multiplex IF images and h quantification of FAP (green) and α-SMA (red) (top row), as well as CD8 (green) and PD-1 (red) (bottom row) in end-point tumors for indicated treatment groups. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. i Quantification of tumor infiltrating endogenous CD8+ T cells and total Tim-3+, TNF-α+, and IFN-γ+ T cells upon re-stimulation ex vivo based on flow cytometry analysis. Data points are mean ± SD (n = 8 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b, d, f, h, and i) or log-rank test (e). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. e MigR+IgG/MigR+anti-PD-1/ FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.004, 0.003 and 0.028, respectively. f CAR T cells: FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.015. g PD-1+ cells: MigR+IgG vs. MigR+Anti-PD-1, p = 0.030; MigR+IgG vs. FAP-CAR+IgG, p = 0.003. i upper left panel: MigR+IgG vs. FAP-CAR+IgG, p = 0.008; FAP+IgG vs. FAP-CAR+anti-PD-1, p = 0.004. upper right panel: MigR+IgG vs. FAP-CAR+IgG, p = 0.003; MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.032; FAP-CAR+IgG vs. FAP-CAR+anti-PD-1, p = 0.025. Bottom panel: TNF-α MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.012; IFN-γ MigR+IgG vs. FAP-CAR+IgG, p = 0.009; MigR+anti-PD-1 vs. FAP-CAR+IgG, p = 0.015. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Ablation of FAP+-CAFs by FAP-CAR T cells enhances the efficacy of subsequent treatment with TAA Meso-CAR T cells in PDAC tumors. a Treatment protocol: C57BL/6 mice bearing established 4662 tumors were treated with the indicated first dose of T cells and 15 days later treated with the second dose of indicated T cells. b Average growth curves, c tumor weights at end-point and d modified Kaplan–Meier curves of mice from each of the indicated treatment groups. e Treatment protocol in established KPC mice. f Average growth curves and g modified Kaplan–Meier curves of KPC mice from each of the indicated treatment groups. h Treatment protocol in NSG mice bearing AsPC-1 human PDAC tumors. i Average growth curves and j modified Kaplan–Meier curves of AsPC-1 human PDAC bearing NSG mice from each of the indicated treatment groups. k Representative multiplexed IF images (top panels) and quantification (bottom panels) of sections of end-point tumors from each of the indicated treatment groups stained for cleaved caspase-3, Ki-67, TGF-β or CD31 (red) as indicated and in each case co-stained with Pan-CK (green). Nuclei were stained with DAPI (blue). Scale bar, 100 μm. Data points are mean±SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b, c, f, i, k) or log-rank test (d, g, j). e The pancreas and ultrasound are created with BioRender.com. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c MigR+MigR/Meso-CAR+MigR vs. FAP-CAR + FAP-CAR, p = 0.005 and 0.022, respectively. d MigR+MigR/Meso-CAR+MigR/Meso-CAR+Meso-CAR/FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003, 0.002, 0.002, 0.002 and 0.002, respectively. g MigR+Meso-CAR/Meso-CAR+Meso-CAR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003, 0.002 and 0.002, respectively. j p = 0.002 for all comparisons. k Ki-67: MigR+MigR/Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR + FAP-CAR, p = 0.008, 0.004 and 0.032, respectively. TGF-β: Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.008 and 0.002, respectively. Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR + FAP-CAR, p = 0.005 and 0.001, respectively. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 6 Ablation of FAP+-CAFs by FAP-CAR T cells enhances the efficacy of subsequent treatment with TAA Meso-CAR T cells in PDAC tumors. a Treatment protocol: C57BL/6 mice bearing established 4662 tumors were treated with the indicated first dose of T cells and 15 days later treated with the second dose of indicated T cells. b Average growth curves, c tumor weights at end-point and d modified Kaplan–Meier curves of mice from each of the indicated treatment groups. e Treatment protocol in established KPC mice. f Average growth curves and g modified Kaplan–Meier curves of KPC mice from each of the indicated treatment groups. h Treatment protocol in NSG mice bearing AsPC-1 human PDAC tumors. i Average growth curves and j modified Kaplan–Meier curves of AsPC-1 human PDAC bearing NSG mice from each of the indicated treatment groups. k Representative multiplexed IF images (top panels) and quantification (bottom panels) of sections of end-point tumors from each of the indicated treatment groups stained for cleaved caspase-3, Ki-67, TGF-β or CD31 (red) as indicated and in each case co-stained with Pan-CK (green). Nuclei were stained with DAPI (blue). Scale bar, 100 μm. Data points are mean±SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b, c, f, i, k) or log-rank test (d, g, j). e The pancreas and ultrasound are created with BioRender.com. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c MigR+MigR/Meso-CAR+MigR vs. FAP-CAR + FAP-CAR, p = 0.005 and 0.022, respectively. d MigR+MigR/Meso-CAR+MigR/Meso-CAR+Meso-CAR/FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003, 0.002, 0.002, 0.002 and 0.002, respectively. g MigR+Meso-CAR/Meso-CAR+Meso-CAR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003, 0.002 and 0.002, respectively. j p = 0.002 for all comparisons. k Ki-67: MigR+MigR/Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR + FAP-CAR, p = 0.008, 0.004 and 0.032, respectively. TGF-β: Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.008 and 0.002, respectively. Meso-CAR+MigR/Meso-CAR+Meso-CAR vs. FAP-CAR + FAP-CAR, p = 0.005 and 0.001, respectively. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 FAP-CAR T cells rendered tumors permissive to Meso-CAR T cells allowing their infiltration and function within tumor. a Treatment protocol: 4662 tumor-bearing CD45.1 C57BL/6 mice (hosts) were treated with donor MigR control, Meso-CAR or FAP-CAR T cells (CD45.2 GFP+). 4 days later, all mice received a second treatment of CD45.2 tdTomato+ Meso-CAR T cells. b Representative static images from two-photon microscopy at different subregions in the tumors treated with MigR control, Meso-CAR, or FAP-CAR T cells (GFP+) with subsequent Meso-CAR T cells (tdTomato+) at indicated time points. The GFP+ T cells from first treatment appear green and tdTomato+ Meso-CAR T cells from second treatment appear red and examples of latter are highlighted by white arrows. CD90.2+ stromal cells appear magenta and mCerulean+ tumor cells cyan. Scale bar, 100 µm. c Quantification of tdTomato+ Meso-CAR T cells (Top panels) and mCerulean+ tumor cells (bottom panels) in stroma-rich (left) and tumor nest (right) regions at day 1, 4 and 7 post administration. Data points (15 per condition) represent measurements in 3 different fields of stroma-rich and 3 different fields of tumor-nest regions from tumor slices from 5 mice per group. d Representative flow plots and quantification of flow cytometry analysis of tdTomato+ Meso-CAR T cells in tumors from the indicated treatment groups at the indicated times post-second treatment. e Quantification of the expression of GzmB, IFN-γ and TNF-α by examined for the infiltrating tdTomato+ Meso-CAR T cells in tumors from each of the indicated treatment groups at the indicated times post-second treatment. Data points are mean±SD (n = 5 per group) and groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests (c, d) or one-way ANOVA analysis with Dunnett’s multiple comparison tests (e). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c % mCerulean+ tumor cell: Day 1 MigR+Meso-CAR/Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.001 and 0.031, respectively. Day 7 Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.004. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 7 FAP-CAR T cells rendered tumors permissive to Meso-CAR T cells allowing their infiltration and function within tumor. a Treatment protocol: 4662 tumor-bearing CD45.1 C57BL/6 mice (hosts) were treated with donor MigR control, Meso-CAR or FAP-CAR T cells (CD45.2 GFP+). 4 days later, all mice received a second treatment of CD45.2 tdTomato+ Meso-CAR T cells. b Representative static images from two-photon microscopy at different subregions in the tumors treated with MigR control, Meso-CAR, or FAP-CAR T cells (GFP+) with subsequent Meso-CAR T cells (tdTomato+) at indicated time points. The GFP+ T cells from first treatment appear green and tdTomato+ Meso-CAR T cells from second treatment appear red and examples of latter are highlighted by white arrows. CD90.2+ stromal cells appear magenta and mCerulean+ tumor cells cyan. Scale bar, 100 µm. c Quantification of tdTomato+ Meso-CAR T cells (Top panels) and mCerulean+ tumor cells (bottom panels) in stroma-rich (left) and tumor nest (right) regions at day 1, 4 and 7 post administration. Data points (15 per condition) represent measurements in 3 different fields of stroma-rich and 3 different fields of tumor-nest regions from tumor slices from 5 mice per group. d Representative flow plots and quantification of flow cytometry analysis of tdTomato+ Meso-CAR T cells in tumors from the indicated treatment groups at the indicated times post-second treatment. e Quantification of the expression of GzmB, IFN-γ and TNF-α by examined for the infiltrating tdTomato+ Meso-CAR T cells in tumors from each of the indicated treatment groups at the indicated times post-second treatment. Data points are mean±SD (n = 5 per group) and groups were compared using two-way ANOVA with Tukey’s multiple comparisons tests (c, d) or one-way ANOVA analysis with Dunnett’s multiple comparison tests (e). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. c % mCerulean+ tumor cell: Day 1 MigR+Meso-CAR/Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.001 and 0.031, respectively. Day 7 Meso-CAR+Meso-CAR vs. FAP-CAR+Meso-CAR, p = 0.004. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 8 Sequential administration of FAP-CAR T cells with Meso-CAR T cells enhances systemic endogenous adaptive anti-tumor immunity in PDAC models. a Treatment protocol. b–d Quantification of tumor-infiltrating endogenous CD8+ T cells and CD4+FoxP3+ Treg cells IFN-γ expression in tumor-infiltrating and splenic endogenous CD8+ T cells upon restimulation ex vivo Ly-6ClowLy-6G+ myeloid cells, CD11b+F4/80+ and CD206+F4/80+ macrophages by flow cytometric analysis. e Representative flow plots and quantification of flow cytometry analysis of CD103+CD11c+ cDC1 cells in tumors from the indicated combination treatment groups. f Representative images (left) and quantification (right) of multiplexed IF staining of sections of end-point tumors from each of the indicated treatment groups stained for CD8 (cyan) and IFN-γ (magenta), CD4 (cyan) and FoxP3 (magenta), F4/80 (cyan) and CD206 (magenta), Gr-1 (cyan) and CD103 (magenta) as indicated and in each case co-stained with EpCAM (yellow). Nuclei were stained with DAPI (blue). Scale bar, 100 μm. Data points are mean ± SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b–f). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. b CD8: FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003 and 0.008, respectively. CD4+FoxP3+: all p = 0.002. c Tumor: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.015; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.004. Spleen: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.002; FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.016 and 0.003, respectively. d Left: p = 0.018; right: MigR+MigR vs. FAP-CAR + FAP-CAR/FAP-CAR+Meso-CAR, p = 0.008 and 0.002, respectively. e. Left: FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.011; right: FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003 and 0.011, respectively. f CD8: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.004. IFN-γ + CD8 + : FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.022. FoxP3: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.034; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.019. F4/80: MigR+MigR/FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.001, 0.014, and 0.018, respectively. Gr-1: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.006; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.020. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.
Fig. 8 Sequential administration of FAP-CAR T cells with Meso-CAR T cells enhances systemic endogenous adaptive anti-tumor immunity in PDAC models. a Treatment protocol. b–d Quantification of tumor-infiltrating endogenous CD8+ T cells and CD4+FoxP3+ Treg cells IFN-γ expression in tumor-infiltrating and splenic endogenous CD8+ T cells upon restimulation ex vivo Ly-6ClowLy-6G+ myeloid cells, CD11b+F4/80+ and CD206+F4/80+ macrophages by flow cytometric analysis. e Representative flow plots and quantification of flow cytometry analysis of CD103+CD11c+ cDC1 cells in tumors from the indicated combination treatment groups. f Representative images (left) and quantification (right) of multiplexed IF staining of sections of end-point tumors from each of the indicated treatment groups stained for CD8 (cyan) and IFN-γ (magenta), CD4 (cyan) and FoxP3 (magenta), F4/80 (cyan) and CD206 (magenta), Gr-1 (cyan) and CD103 (magenta) as indicated and in each case co-stained with EpCAM (yellow). Nuclei were stained with DAPI (blue). Scale bar, 100 μm. Data points are mean ± SD (n = 5 per group) and groups were compared using one-way ANOVA analysis with Dunnett’s multiple comparison tests (b–f). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. b CD8: FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003 and 0.008, respectively. CD4+FoxP3+: all p = 0.002. c Tumor: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.015; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.004. Spleen: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.002; FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.016 and 0.003, respectively. d Left: p = 0.018; right: MigR+MigR vs. FAP-CAR + FAP-CAR/FAP-CAR+Meso-CAR, p = 0.008 and 0.002, respectively. e. Left: FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.011; right: FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.003 and 0.011, respectively. f CD8: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.004. IFN-γ + CD8 + : FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.022. FoxP3: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.034; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.019. F4/80: MigR+MigR/FAP-CAR+MigR/FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.001, 0.014, and 0.018, respectively. Gr-1: MigR+MigR vs. FAP-CAR + FAP-CAR, p = 0.006; FAP-CAR + FAP-CAR vs. FAP-CAR+Meso-CAR, p = 0.020. The p values for remaining comparisons are all <0.001 or <0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 328

Metadata

Authors
Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., Guo, W., Scholler, J., Liousia, M., Assenmacher, C.-A., June, C. H., Albelda, S. M., & Puré, E.
Affiliations
University of Pennsylvania (US)
Corresponding author
Puré, Ellen
Venue
Nature Communications
Published
2023-08-22
Volume
14
Issue
1
Pages
5110-5110
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4386067114
Cited by
272
References
63
Citations by year
2026: 110 · 2025: 94 · 2024: 59 · 2023: 9
FWCI
33.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Research Institute (CRI4168)
  • University of Pennsylvania (P30 DK050306, P30CA016520)
  • Abramson Cancer Center (P30CA016520)
  • National Institutes of Health (CA016520, T35OD010919)
  • National Cancer Institute (CA016520, P01CA066726, P01CA217805, P30CA016520)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050306)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords
desmoplastic stroma, T cell extravasation, immune exclusion, immunosuppression, solid tumors, pancreatic cancer, chimeric antigen receptor T cells, fibroblast activation protein, cancer-associated fibroblasts, mesothelin, anti-PD-1 therapy, tumor microenvironment, NK cell infiltration, CD8+ T cells, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. https://app.cochat.ai/papers/10.1038/s41467-023-40850-5
The paper
Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., Guo, W., Scholler, J., Liousia, M., Assenmacher, C.-A., June, C. H., Albelda, S. M., & Puré, E. (2023). Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nature Communications. https://doi.org/10.1038/s41467-023-40850-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.